<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308645</url>
  </required_header>
  <id_info>
    <org_study_id>SB Injection HCC</org_study_id>
    <nct_id>NCT01308645</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)</brief_title>
  <acronym>HCC</acronym>
  <official_title>PhaseⅡ, Open Label, Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SBPharmaceutical IND, Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SBPharmaceutical IND, Co., LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of SB injection in Hepatocellular&#xD;
      Carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients will receive SB injection therapy for 6 cycles (14~21 days for each&#xD;
      cycle). Efficacy wll be evaluated every 3 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating Tumor Response Rate</measure>
    <time_frame>4 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability scale</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine duration of response rate by measuring time to progression</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB injection</intervention_name>
    <description>Infusion SB injection of 21.87 ml/m^2, IV route, 24 times for 4 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of 18 years or over&#xD;
&#xD;
          2. Patients with Hepatocellular carcinoma progression (HCC) and primary liver cancer as a&#xD;
             diagnostic imaging test (eg, X-ray, CT, scan, ultrasound) can be measured in patients&#xD;
             with a lesion&#xD;
&#xD;
          3. Directly to standard therapy (surgery, RF ablation, TACE) is not possible, patients&#xD;
             with advanced liver cancer. However, the standard treatment of the subject or subjects&#xD;
             entirely voluntary participation of subjects participating at the discretion of the&#xD;
             doctor or researcher can be deemed included in the selected target.&#xD;
&#xD;
          4. Life expectancy ≥ 5 months&#xD;
&#xD;
          5. ECOG status 0, 1, 2 patients&#xD;
&#xD;
          6. Child-Pugh classification A, B patients&#xD;
&#xD;
          7. PLT 70,000, ANC 1,000 or more patients (OT / PT &lt;upper normal limit x 5.0, Bilirubin&#xD;
             &lt;upper normal limit x 3.0)&#xD;
&#xD;
          8. Female volunteers admitted to the study must be using a reliable means of&#xD;
             contraception and must have a negative blood or urine pregnancy test at least 7 days&#xD;
             ago&#xD;
&#xD;
          9. Patients or their legal representatives who have signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Last 4 weeks the patients who had participated in another clinical trial&#xD;
&#xD;
          2. Last 4 weeks the patients who received chemotherapy&#xD;
&#xD;
          3. Associated with hepatocellular carcinoma in patients with a history of malignant tumor&#xD;
&#xD;
          4. Hepatectomy or liver transplantation patients who received treatment.&#xD;
&#xD;
          5. Active systemic infection requiring medical treatment&#xD;
&#xD;
          6. Uncontrolled hypertension or diabetes mellitus.&#xD;
&#xD;
          7. Clinically Significant cardiac disease (myocardial infarction / angina / severe&#xD;
             arrhythmia / congestive heart failure)&#xD;
&#xD;
          8. Autoimmune diseases (systemic lupus erythematosus: SLE / rheumatoid arthritis /&#xD;
             myasthenia gravis) and the patients currently being treated&#xD;
&#xD;
          9. Presence or history of malignancy other than Hepatocellular carcinoma within 5 years&#xD;
&#xD;
         10. Patients who have history of allergy with this investigational drug.&#xD;
&#xD;
         11. Obvious cognitive or physical impairment that would prevent participation&#xD;
&#xD;
         12. Pregnancy, lactation period and don't using contraception earnest Patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Jin woo, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee Jin woo, Prof.</last_name>
    <phone>82-32-3598</phone>
    <email>jin@inha.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lee Ji yeon, RN/BSc</last_name>
    <phone>82-32-890-1133</phone>
    <email>twindleclara@inha.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Jung-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jin woo, prof.</last_name>
      <phone>28-32-890-3598</phone>
      <email>jin@inha.com</email>
    </contact>
    <contact_backup>
      <last_name>Lee Ji yeon, RN/BSc</last_name>
      <phone>82-32-890-1133</phone>
      <email>twinkleclara@inha.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lee Jin woo, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sbp.com</url>
    <description>Link Text : SBP</description>
  </link>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>March 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lee Dong-heum / executive director</name_title>
    <organization>SBPharmaceutical IND, Co., LTD</organization>
  </responsible_party>
  <keyword>SBP Injection</keyword>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

